Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$21.86 -2.1%	$18.80	$6.49 ▼ $23.64	$5.17B	0.53	3.64 million shs	2.61 million shs
AMAM Ambrx Biopharma	$28.00	$27.94	$6.55 ▼ $28.15	$1.77B	-1.92	2.12 million shs	N/A
KRYS Krystal Biotech	$168.06 -0.6%	$176.37	$141.72 ▼ $219.34	$4.86B	0.75	296,112 shs	171,300 shs
RVMD Revolution Medicines	$38.77 +0.5%	$37.43	$29.17 ▼ $62.40	$7.21B	1.37	1.43 million shs	1.08 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+2.58%	+7.79%	+35.95%	+238.39%
AMAM Ambrx Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%
KRYS Krystal Biotech	0.00%	-0.30%	-8.04%	+8.56%	+5.66%
RVMD Revolution Medicines	0.00%	+5.47%	+1.76%	-5.42%	+8.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	1.5118 of 5 stars	1.6	1.0	0.0	0.0	3.6	1.7	1.9
AMAM Ambrx Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	4.9029 of 5 stars	4.5	3.0	0.0	4.7	3.0	3.3	1.9
RVMD Revolution Medicines	3.7914 of 5 stars	3.5	0.0	0.0	4.7	3.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.25	Buy	$22.50	2.93% Upside
AMAM Ambrx Biopharma	0.00	N/A	N/A	N/A
KRYS Krystal Biotech	3.00	Buy	$220.00	30.91% Upside
RVMD Revolution Medicines	3.00	Buy	$66.67	71.95% Upside

Current Analyst Ratings Breakdown

Latest AMAM, RVMD, ADMA, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00 ➝ $59.00
4/1/2025	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $64.00
3/5/2025	KRYS Krystal Biotech	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$245.00
3/4/2025	ADMA ADMA Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
3/3/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $73.00
2/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$221.00 ➝ $221.00
2/27/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
2/27/2025	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
2/27/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $59.00
2/20/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$206.00 ➝ $215.00
2/20/2025	KRYS Krystal Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$215.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	12.12	$0.07 per share	311.70	$0.60 per share	36.43
AMAM Ambrx Biopharma	$7.40M	238.95	N/A	N/A	$3.05 per share	9.18
KRYS Krystal Biotech	$290.52M	16.72	$4.27 per share	39.38	$32.85 per share	5.12
RVMD Revolution Medicines	$742K	9,714.08	N/A	N/A	$11.09 per share	3.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	-$28.24M	$0.82	78.07	31.68	N/A	17.80%	53.20%	26.07%	5/8/2025 (Estimated)
AMAM Ambrx Biopharma	-$78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	$10.93M	$2.99	56.21	16.67	N/A	30.69%	11.41%	10.40%	5/6/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$3.57	N/A	N/A	N/A	N/A	-33.67%	-30.08%	5/6/2025 (Estimated)

Latest AMAM, RVMD, ADMA, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	RVMD Revolution Medicines	-$1.10	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ADMA ADMA Biologics	$0.16	N/A	N/A	N/A	$116.40 million	N/A
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.35	N/A	N/A	N/A	$98.66 million	N/A
2/26/2025	Q4 2024	RVMD Revolution Medicines	-$1.01	-$1.12	-$0.11	-$1.12	$0.35 million	N/A
2/24/2025	Q4 2024	KRYS Krystal Biotech	$1.29	$1.52	+$0.23	$1.52	$91.35 million	$91.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AMAM Ambrx Biopharma	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.48	7.09	3.26
AMAM Ambrx Biopharma	N/A	13.28	13.28
KRYS Krystal Biotech	N/A	7.28	7.76
RVMD Revolution Medicines	N/A	14.24	14.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AMAM Ambrx Biopharma	77.28%
KRYS Krystal Biotech	86.29%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.70%
AMAM Ambrx Biopharma	0.64%
KRYS Krystal Biotech	13.70%
RVMD Revolution Medicines	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	236.39 million	227.64 million	Optionable
AMAM Ambrx Biopharma	87	63.15 million	62.75 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.71 million	Optionable
RVMD Revolution Medicines	250	185.91 million	154.76 million	Optionable

AMAM, RVMD, ADMA, and KRYS Headlines

Recent News About These Companies

Hood River Capital Management LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 25 at 7:19 AM | marketbeat.com

Rock Springs Capital Management LP Grows Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 23, 2025 | marketbeat.com

Raymond James Financial Inc. Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 23, 2025 | marketbeat.com

Wells Fargo & Company MN Has $3.86 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 23, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Barclays PLC

April 22, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by Nan Fung Group Holdings Ltd

April 21, 2025 | marketbeat.com

Altium Capital Management LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 20, 2025 | marketbeat.com

Marshall Wace LLP Acquires 439,802 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

April 20, 2025 | marketbeat.com

Walleye Capital LLC Sells 111,076 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

April 18, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Recommendation of "Buy" from Brokerages

April 14, 2025 | marketbeat.com

Fmr LLC Has $294.90 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 13, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Alliancebernstein L.P.

April 13, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns Buy Rating from Needham & Company LLC

April 10, 2025 | marketbeat.com

ADAR1 Capital Management LLC Has $7.44 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 9, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stake Decreased by Finepoint Capital LP

April 8, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Geode Capital Management LLC

April 8, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year Low - Here's Why

April 7, 2025 | marketbeat.com

ExodusPoint Capital Management LP Acquires Shares of 123,315 Revolution Medicines, Inc. (NASDAQ:RVMD)

April 7, 2025 | marketbeat.com

California Public Employees Retirement System Has $11.74 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

April 7, 2025 | marketbeat.com

75,000 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Pamalican Asset Management Ltd

April 6, 2025 | marketbeat.com

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

April 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off?
By Jeffrey Neal Johnson | April 4, 2025
View Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off?

AMAM, RVMD, ADMA, and KRYS Company Descriptions

ADMA Biologics NASDAQ:ADMA

$21.86 -0.47 (-2.10%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$21.97 +0.11 (+0.52%)

As of 04/25/2025 07:57 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Ambrx Biopharma NYSE:AMAM

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Krystal Biotech NASDAQ:KRYS

$168.06 -1.06 (-0.63%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$169.00 +0.94 (+0.56%)

As of 04/25/2025 06:30 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Revolution Medicines NASDAQ:RVMD

$38.77 +0.19 (+0.49%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$39.50 +0.73 (+1.89%)

As of 04/25/2025 07:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time